HSC is currently in a Phase I/II clinical trial in the Philippines. We look forward to sharing data from that trial in the coming months. Due to the timelines associated with clinical trials and regulatory approval, the estimated timeframe for market availability of HSC continues to be 2015/2016 within the US. There is a possibility of earlier introduction in certain Pan-Asian countries, and plans for additional regions have not yet been finalized.
Histogen intends to bring HSC to market through partnerships with industry leaders in various regions. As such, it will be our partner that ultimately determines the market price point. We are likely to have a better idea for potential price range as HSC gets closer to market.
Histogen intends to bring HSC to market through partnerships with industry leaders in various regions. As such, it will be our partner that ultimately determines the market price point. We are likely to have a better idea for potential price range as HSC gets closer to market.
Comment